(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Wednesday reported positive results from the preclinical study of its lead drug candidate HT-ALZ for the treatment of Alzheimer's disease. HT-ALZ has ...

NEW YORK, March 31, 2025 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK, March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases ...

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors. The results highlight HT ...

Short interest in Hoth Therapeutics Inc (NASDAQ:HOTH) decreased during the last reporting period, falling from 231.49K to 174.06K. This put 1.33% of the company's publicly available shares short.